MARKET

BLRX

BLRX

Biolinerx
NASDAQ
2.800
+0.030
+1.08%
After Hours: 2.973 +0.173 +6.18% 18:43 01/02 EST
OPEN
2.760
PREV CLOSE
2.770
HIGH
2.960
LOW
2.710
VOLUME
26.23K
TURNOVER
--
52 WEEK HIGH
14.70
52 WEEK LOW
2.300
MARKET CAP
12.18M
P/E (TTM)
-2.1585
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BLRX last week (1222-1226)?
Weekly Report · 12/29/2025 09:51
Weekly Report: what happened at BLRX last week (1215-1219)?
Weekly Report · 12/22/2025 09:51
Weekly Report: what happened at BLRX last week (1208-1212)?
Weekly Report · 12/15/2025 09:56
Weekly Report: what happened at BLRX last week (1201-1205)?
Weekly Report · 12/08/2025 09:55
Weekly Report: what happened at BLRX last week (1124-1128)?
Weekly Report · 12/01/2025 09:52
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges
TipRanks · 11/26/2025 00:06
BioLineRx Reports Q3 2025 Results and Strategic Expansion
TipRanks · 11/25/2025 03:53
BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate
Benzinga · 11/24/2025 22:36
More
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.